Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04380584
Other study ID # N-4-2020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 30, 2019
Est. completion date March 29, 2020

Study information

Verified date May 2020
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Diabetic nephropathy (DN) is the commonest cause of chronic kidney disease, and proteinuria isn't determent factor for the end stage renal disease in diabetics. Apelin is adipokine and have a beneficial role in early prediction of diabetic nephropathy. Few studies were done about apelin in diabetes. Purpose of the study: to investigate the association between the apelinergic system and diabetic nephropathy.


Description:

Introduction Type 2 Diabetes Mellitus is a metabolic syndrome associated with hyperglycemia due to defect in secretion or action of insulin or both. Long term hyperglycemia leads to complications of microvasculature involving the eyes, kidneys and nerves.

Diabetic nephropathy (DN) is the commonest cause of end-stage renal disease that may need hemodialysis up to renal transplantation with increased incidence of mortality. Without management, patients with diabetes worsen from micro albuminuria to frank proteinuria with more impairment of kidney functions. This worsening develops in both type 1 and type 2 diabetes.Previous studies have revealed major roles of different inflammatory molecules in the development of diabetic nephropathy, including acute phase reactants, inflammatory cytokines, adhesion molecules, and chemokines.

Previous studies have revealed major roles of different inflammatory molecules in the development of diabetic nephropathy, including acute phase reactants, inflammatory cytokines, adhesion molecules.

Apelin (APLN) is the endogenous ligand peptide which is encoded in humans by the APLN gene. It is presented widely in different organs as the heart, kidney, liver, fatty tissue, endothelium, plasma, gastrointestinal tract, brain and adrenals .Apelin has a major role in the pathophysiology of hypertension, heart failure, cardio-vascular disease, DM, and obesity. Apelin is found to be higher in type 2 diabetic patients than healthy subjects. It inhibits insulin secretion, so it may precipitates impaired metabolism of glucose.

Also, Apelin present in omental fat is higher than its presence in subcutaneous fat suggesting its contribution to central obesity which is an important risk factor for type 2 DM.

In diabetic nephropathy, the apelin-13 level is markedly higher in than non-diabetic organs. Apelin mediates podocyte apoptosis,that is inversely related with podocyte autophagy in nephropathic diabetic mice. In addition, the mTOR pathway is supposed to have responsibility for inhibiting podocyte autophagy by apelin.

Apelin participates in the pathology of glomerular angiogenesis by affecting the permeability in glomeruli and glomerular endothelial cells proliferation of diabetics. So, playing a role in DN pathogenesis. Also, administration of apelin-13 diabetic rats restored the down regulation of the antioxidant catalase, revealing its renal protective effect via antioxidant pathways.

We aimed from this work to evaluate the relation between plasma Apelin level and diabetic nephropathy in Egyptian Type 2 diabetic patients.

Materials and methods After approval by the research ethical committee of Kasr El Ainy faculty of medicine, Cairo University on research protocols. A case control study including 90 patients aged 20 to 65 years, 30 healthy subjects as a control group and 60 patients with type 2 DM .Patients were collected from the endocrinology outpatient clinic, Kasr El Ainy, Cairo university. It was conducted from November 2019 to march 2020.

Oral consent was obtained from patients before inclusion after explaining the study protocol. Patients were divided into 3 groups, (group I) 30 patients with type 2 DM with nephropathy, (group II) 30 type 2 DM without nephropathy and (group III) 30 non DM as control group. Exclusion criteria included Patients with nephropathy due to other causes than diabetes, hepatic, intrinsic renal or coronary artery disease, patients with diabetic neuropathy and retinopathy and hypertensive patient on angiotensin receptor blockers (ARBS) or angiotensin converting enzyme inhibitors (ACEI) treatment as it affect Apelin level.

Full medical history was taken from all subjects, emphasizing on age , duration of diabetes mellitus, complications specially nephropathy and other co-morbid conditions and full clinical examination including blood pressure measurement, weight, height, Body Mass Index (BMI) (kg/m2) and waist circumference .

Laboratory investigations in the form of fasting blood glucose (FBG), 2 hr- postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low densitylipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), glycosylated hemoglobin (Hb A1c), urea, creatinine, urine analysis , albumin creatinine ratio , estimated glomerular filtration rate (e GFR) , glycosylated hemoglobin (Hb A1c), and Apelin levels were assessed.

Sampling: Five ml of venous blood was collected by venipuncture was divided into 3 parts: The first part was 2 ml of blood added to a tube containing EDTA for determination of HbA1C by caution exchange resin. The 2nd part was 3 ml of blood was left in plastic serum tubes and the specimens were allowed to clot at room temperature then serum was separated from the cells as soon as by centrifugation at 3000xg for 5 minutes. The separated serum was stored at -20ºC until analysis. The 3rd part was collected in a tube containing EDTA and centrifuged for 15 min at 1000×g at 2-8℃ within 30 min of collection. The supernatant was collected and stored at -80ºC for apelin determination.

Determination of serum urea, serum creatinine, serum total cholesterol, serum triglyceride, serum LDL and serum HDL were carried out on Dimension RxL Max analyzer, (Siemens Healthcare GmbH - Henkestr. 127, 91052 Erlangen, Germany) by colorimetric techniques.

Plasma apelin was determined using competitive-ELISA kit supplied from Elabscience Biotechnology Inc., (1 Shizishan Street, Hongshan District, Wuhan, Hubei, China) , ( Estienne A et al . 2019). eGFR was estimated using Cockcroft Gault equation: Cockcroft Gault equation= 140-age x weight/72 x S.Cr mg/dl(x 0.85 in female).

Complete urine analysis was done to detect the presence of active urinary sediment (proteinuria, pyuria, RBCs or RBCs casts, granular cast).

Albumin concentrations were measured in urine using a Minineph micro albumin kit based on nephelometry method on Minineph-nephelometer. Urinary creatinine was determined on Dimension RxL Max analyzer by colorimetric technique and the ratio of urine albumin to creatinine was used to define micro albuminuria.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date March 29, 2020
Est. primary completion date March 20, 2020
Accepts healthy volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- type 2 diabetes patients of both sexes ,20-60 years of age

Exclusion Criteria:

- Patients with nephropathy due to other causes than diabetes, hepatic, intrinsic renal or coronary artery disease, patients with diabetic neuropathy and retinopathy and hypertensive patient on angiotensin receptor blockers (ARBS) or angiotensin converting enzyme inhibitors (ACEI)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
plasma Apelin level
blood sample for detection of plasma Apelin level

Locations

Country Name City State
Egypt Cairo university hospitals Cairo Manial

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

1. American Diabetes Association (ADA) .2012. Diagnosis of diabetes mellitus.2012 .Diabetes 291 Care;35. suppl S64- S71. doi: 10.2337/dc12-s064 . 292 2. Bonnet F and Cooper ME. 2000. Potential influence of lipids in diabetic nephropathy:insights 293 from experimental data and clinical studies. Diabetes Metab.;26:254-64. 294 3. Chan YH. 2003: Biostatistics102: Quantitative Data - Parametric & Non-parametric Tests. 295 Singapore Med J.;44(8): 391-396. 296 4. Chan YH. 2003: Biostatistics 104: Correlational Analysis. Singapore Med J.;44(12) : 614- 297 619.

Outcome

Type Measure Description Time frame Safety issue
Primary prediction of diabetic nephropathy the use of plasma apelin level as a predictor for development of diabetic nephropathy 12 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Terminated NCT01575379 - A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Phase 4
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Not yet recruiting NCT04084886 - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Active, not recruiting NCT04869761 - Stem Cell Therapy for Chronic Kidney Disease Phase 1
Recruiting NCT04570735 - MRI Biomarkers in Diabetic Kidney Disease
Completed NCT03165240 - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated Phase 1
Completed NCT01968668 - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) Phase 2
Completed NCT02552277 - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy Phase 2
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Terminated NCT02410005 - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL) Phase 2/Phase 3
Unknown status NCT01918488 - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT03165227 - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) Phase 1
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Completed NCT03618420 - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Phase 1/Phase 2
Not yet recruiting NCT03284996 - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus. N/A
Completed NCT03334318 - PERL Continuous Glucose Monitoring (CGM) Study
Recruiting NCT01320345 - The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. Phase 3